Who is sponsoring NCT00577161?

NCT00577161 is sponsored by CTI BioPharma.

What condition does NCT00577161 study?

NCT00577161 studies Non-Hodgkin's Lymphoma.

What drugs are being tested in NCT00577161?

Interventions: fludarabine and rituximab, fludarabine, rituximab, pixantrone.

What is the status of NCT00577161?

NCT00577161 is currently WITHDRAWN.

Last reviewed 2020-10-02 · How we verify

Fludarabine, BBR 2778 (Pixantrone) and Rituximab (FP-R) vs Fludarabine and Rituximab (F-R) for Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

NCT00577161 Phase 3 WITHDRAWN

BBR 2778 is a novel aza-anthracenedione that has activity in experimental tumors and reduced delayed cardiotoxicity in animal models compared to reference standards. This cytotoxic agent has structural similarities to mitoxantrone as well as general similarities to anthracyclines (such as the tricyclic central quinoid chromophore7). This phase III study will compare the efficacy and safety of the combination BBR 2778, fludarabine, and rituximab with the combination fludarabine and rituximab in patients with relapsed or refractory indolent non-Hodgkin's lymphoma.

Details

Lead sponsor	CTI BioPharma
Phase	Phase 3
Status	WITHDRAWN
Start date	2007-09
Completion	2012-07

Conditions

Non-Hodgkin's Lymphoma

Interventions

fludarabine and rituximab
fludarabine, rituximab, pixantrone

Primary outcomes

progression-free survival — day 64-71

Countries

United States